Overview

Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia

Status:
Not yet recruiting
Trial end date:
2021-12-14
Target enrollment:
Participant gender:
Summary
the investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of Xiyanping injection in patients with 2019-nCoV pneumonia.
Details
Lead Sponsor:
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Treatments:
Interferon-alfa-1b
Interferon-alpha
Interferons
Lopinavir
Ritonavir